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Abstract
Background: Epigenetic regulators play a critical role in the maintenance of specific chromatin domains in an
active or repressed state. Disruption of epigenetic regulatory mechanisms is widespread in cancer cells and largely
contributes to the transformation process through active repression of tumor suppressor genes. While mutations of
epigenetic regulators have been reported in various lymphoid malignancies and solid cancers, mutation of these
genes in HTLV-I-associated T-cell leukemia has not been investigated.
Method: Here we used whole genome next generation sequencing (NGS) of uncultured freshly isolated ATL
samples and identified the presence of mutations in SUZ12, DNMT1, DNMT3A, DNMT3B, TET1, TET2, IDH1, IDH2,
MLL, MLL2, MLL3 and MLL4.
Results: TET2 was the most frequently mutated gene, occurring in 32 % (10/31) of ATL samples analyzed. Interestingly,
NGS revealed nonsense mutations accompanied by loss of heterozygosity (LOH) in TET2 and MLL3, which was further
confirmed by cloning and direct sequencing of DNA from uncultured cells. Finally, direct sequencing of matched
control and tumor samples revealed that TET2 mutation was present only in ATL tumor cells.
Conclusions: Our results suggest that inactivation of MLL3 and TET2 may play an important role in the tumorigenesis
process of HTLV-I-induced ATL.
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Background
Human T-cell leukemia virus type I (HTLV-I) is associ-
ated with fatal lymphoproliferative disorders known as
adult T-cell leukemia/lymphoma (ATL) [1, 2]. The dis-
ease is classified into distinct subtypes - smoldering,
chronic, acute and lymphoma - that differ in their clin-
ical presentation and in their response to treatment [3].
Since the clinical subtypes of ATL have distinct genomic
alterations and different clinical progression, these dis-
eases require a different approach for treatment [4].
However, current therapies for ATL do not result in
long-term remission and even the clinically less aggres-
sive forms ultimately evolve to the acute. The 4 year
survival rate for acute-, lymphoma-, chronic- and
smoldering-type ATL is 11, 16, 36, and 52 %, respect-
ively [5, 6]. The viral oncoprotein Tax plays an import-
ant role in initiation of events leading to cellular
transformation [7, 8]. However, the fact that the disease
has a low penetrance and is observed after a long latency
period of several decades has led to the hypothesis that
the virus initiates oncogenic events but is not sufficient
for cellular transformation [9, 10]. In support of this no-
tion epigenetic alterations are required for the develop-
ment of ATL. Promoter hyper-methylation associated
with loss of SHP1 expression coincides with the IL-2-
independent transformation of T cells by HTLV-I in
vitro [11]. SHP1 is one of the most frequently altered
genes in ATL patients, with an overall hyper-
methylation rate of 90 % [12]; other tumor suppressor
genes inactivated by methylation in ATL include p53-
* Correspondence: cnicot@kumc.edu
1Department of Pathology, Center for Viral Oncology, University of Kansas
Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
Full list of author information is available at the end of the article
© 2016 Yeh et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yeh et al. Molecular Cancer  (2016) 15:15 
DOI 10.1186/s12943-016-0500-z
related p73, CDKN2A and p21CIP1/WAF1 [13]. The
fact that histone methyl-transferase EZH2 has been
demonstrated to repress p57KIP2 expression through
histone H3 lysine 27 trimethylation (H3K27me3) [14],
and that p57KIP2 is methylated in nearly 50 % of newly
diagnosed ALL patients [15], prompted us to analyze the
status of cellular genes involved in chromatin silencing.
In this study we use next generation sequencing (NGS)
to characterize the genetic mutations in EZH1, EZH2,
EED, SUZ12, DNMT1, DNMT3A, DNMT3B, TET1,
TET2, TET3, IDH1/2, MLL, MLL2, MLL3, MLL4 and
ASXL1. Our study revealed a high frequency of muta-
tion in epigenetic regulators in ATL samples, suggesting
that chromatin remodeling by some of these genes may
play a role in the pathogenesis of ATL.
Methods
ATL patient samples
All patient samples were obtained after informed con-
sent was provided and in agreement with regulations for
the protection of human subjects according to the
National Institutes of Health (NIH) guidelines. As for
the samples from the Japanese material bank, they were
provided from the biomaterial bank of the Japanese na-
tionwide cohort study (Joint Study of Predisposing Fac-
tors for ATL Development, JSPFAD) that is approved by
the ethical committee of the University of Tokyo (No.
14-15, No. 07-07 and No. 10-50). Genomic DNA was
extracted using DNAZol (Invitrogen) from uncultured
acute and lymphoma ATL samples. DNA samples 1–7,
10 and 11 were isolated from patients diagnosed with
acute ATL. DNA samples 8, 9, 12 and 13 were isolated
from patients with lymphoma ATL. HTLV-I proviral
load was calculated by TaqMan real time PCR and
compared with a standard curve established using
C91PL HTLV-I transformed cell line harboring one pro-
viral copy (Fig.1a). High tumor grade lymph node biopsy
was used for ATL lymphoma patients as confirmed by
real time PCR compared with B cells isolated from
matched patient (Fig.1b).
Next generation sequencing (NGS)
Exome Sequencing was performed by Perkin Elmer.
DNA samples were evaluated using an e-gel and Pico-
Green fluorometry to measure quality and quantity,
respectively. DNA samples were then physically sheared
to the desired size using a Covaris E220 Focused-
ultrasonicator. Library preparation and enrichment were
carried out using an Agilent SureSelectXT All Exon V3
kit and an automated sample preparation method de-
rived from the manufacturer’s protocol. All subsequent
steps were based on sequencing by Next Generation Se-
quencing methods on the Illumina Hiseq 2000 platform.
Basecall files (*.bcl) were generated by the Illumina in-
struments and de-multiplexed and converted to fastq.gz
format using CASAVA v1.8.2. Each pair of fastq.gz files
was then aligned against human reference build 37 using
BWA, v0.6.2. The resulting SAM files were converted to
BAM format, sorted and indexed using SamTools
v0.1.18. Duplicate reads in the sorted BAM file were
marked using PicardTools v1.86. The duplicate marked
BAM files were processed using GATK v1.6–13, follow-
ing their “Best-Practices V3”. Each BAM was realigned
around known INDELs and base quality scores were
recalibrated, resulting in a recalibrated BAM file. Vari-
ants for each recalibrated BAM file were called using
GATK Unified Genotyper, with SNPs and INDELs saved
to separate files. These files were then hard filtered.
Fig. 1 a A set of standard samples was prepared through dilution of HTLV-I transformed cell line DNA (TL) containing a single copy of integrated
HTLV-I with HTLV-I negative 293 T cell DNA. Real time PCR was performed with 100 ng of mixed DNA. Both GAPDH and gag were detected and
ΔCt was calculated by Ct gag - Ct GAPDH. The standard curve was created with ΔCt (X) and the percentage of HTLV-I viral load relative to TL cell
(Y). b Proviral load was calculated in DNA samples isolated from high grade ATL lymphoma and matched-control B cells by real time PCR. Relative
proviral loads were calculated using the standard curve established above
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Direct PCR-sequencing and TA cloning for analyses
Direct sequencing of ATL DNA was performed after PCR
amplification using specific primers described below. In
the case of MLL3 primers were located in introns sur-
rounding exon 16. Primers amplify genome sequence
from 152235498 to 152236241 of chromosome seven
which encompass the MLL3 Exon16 nucleotide 2653 to
2769 (amino acid 884 to 923). MLL3 F: CAGGCTA-
TAGTTGTTGTCGTCACCAAG; MLL3 R: CATAACAT-
GATAGTAAGCAAATATCTATC. TET2-414 primers
amplify nucleotide 842 to 1379 exon1 of TET2, which cor-
respond to TET2 amino acid 281 to 459. TET2 Q414-F:
ACTCTGAGCTGCCTCCAAAG; TET2 Q414-R: GAAG
GTGGTGCCTCAGGTTT. TET2-876 primers amplify
nucleotide 2403 to 2866 exon1 of TET2, which corres-
pond to amino acid 801 to 955. TET2 Q876-F:
TGTCCAAATGGGACTGGAGG; TET2 Q876-R: GATG
CCACCTTAGAGCAGCA. Individual clones were ob-
tained by TA-cloning (Invitrogen) and five clones were
sequenced.
Results
Despite profound epigenetic alterations in the genome
of ATL cells, the genetic status of chromatin modifiers
has not been investigated. In this study we performed
next generation exome sequencing (NGS) to identify
novel mutations in epigenetic regulators in ATL sam-
ples. The polycomb repressive complex 2 (PRC2) has
histone methyltransferase activity and primarily tri-
methylates histone H3 on lysine 27 (H3K27me3), a mark
of transcriptionally silent chromatin [16]. The PRC2
complex has four subunits: SUZ12, EED, EZH1 and
EZH2. LOH mutations of EZH2 or SUZ12 have been re-
ported in 25 % of T-ALL [17]. In addition, the loss of
PRC2 activity cooperates with mutated Notch1 by allow-
ing recruitment of the intracellular domain of Notch
onto the promoter of target genes [17]. Along these
lines, activated Notch is also required for ATL cell
growth and tumor formation in an ATL mouse model
[18]. While the EZH2 gene was not mutated in our
study, 1/13 ATL sample had a mutation in SUZ12 (Add-
itional file 1: Table S1). It will be interesting in future
studies to investigate if there is any cooperation of EZH2
and/or SUZ12 with activated Notch in a larger cohort of
acute ATL patients. The coding sequence of the other
two subunits, EED and EZH1, was not mutated in any of
the ATL samples tested. The possibility that some mem-
bers of PRC2 may be regulated post-transcriptionally by
microRNA or LncRNA in ATL cells is under investiga-
tion. Similarly, miR101, miR-26 and miR208b have been
shown to target EZH2, miR-323-3p to target EED, and
miR-200b to target SUZ12. An earlier study demon-
strated that decreased expression of miR-101, but not
MiR-26b, in acute ATL is in part responsible for elevated
expression of EZH2 in these cells [19]. Consequently, in-
creased expression of the EZH2 protein induced the si-
lencing of miR-31, resulting in NIK-mediated activation
of NF-kB in ATL cells [20]. Additional sex combs like
transcriptional regulator 1 (ASXL1) interact with PRC2
and are likely involved in a cross-talk between chromatin
silencing systems, PRC1/PRC2, the HP1α/CBX5 hetero-
chromatin repressive complex and the polycomb repres-
sive deubiquitinase (PR-DUB) complex. Mutation of
ASXL1 has been reported in AML and chronic myelo-
monocytic leukemia (CMML) patients [21]. Our study
revealed mutations of ASXL1 in 2/13 ATL samples
(Additional file 1: Table S1). Interestingly, an ASXL1
somatic mutation, V1092M, detected in one ATL patient
has also been reported in myeloproliferative neoplasms
(MPN) and myelodysplastic syndromes (MDS) [22].
We next analyzed DNA (cytosine-5)-methyltransferases
(DNMT1, DNMT3A and DNMT3B), which catalyze the
transfer of methyl groups to specific CpG islands in DNA
and are involved in maintenance or de novo methylation.
Somatic mutations in DNMT3A have been reported as
nonsense, frameshift, and missense mutations throughout
the open-reading frame in 5–20 % of AML and MDS [23].
These studies suggested a potential gain-of-function that
did not require the presence of a wild type copy of
DNMT3A for altered function. Our analyses identified
mutations in 7.5 % (1/13) of DNMT1 (isoform a) and
DNMT3A (isoform b) and 15 % (2/13) of DNMT3B (iso-
form 1) of ATL samples. Interestingly, the same mutation
at position N442K of DNMT3B was identified in two dif-
ferent unrelated ATL patients and has been reported in
prostate cancer cells and the Cosmic Database.
The Mixed Lineage Leukemia (MLL) family of genes
(also known as lysine (K)-specific methyltransferases
(KMT2)) plays an important role in histone methylation
and transcriptional activation and is involved as a regu-
lator of growth of hematopoietic precursor cells. Muta-
tion of MLL and MLL2 was observed in 7.5 % (1/13) of
ATL patients. The MLL3 gene, which encodes a compo-
nent of a histone H3 lysine 4 methyltransferase complex
named the ASC-2- and Mll3-containing complex
(ASCOM), has been implicated as a tumor suppressor
gene due to its frequent mutations in multiple types of
human tumors [24]. Exome sequencing has recently
been used to identify an MLL3 germ line mutation in a
pedigree of colorectal cancer and acute myeloid
leukemia [25]. Mutations and LOH in MLL3 has been
reported in various human cancers [26]. Our initial NGS
analyses identified a high rate of nonsense mutations in
MLL3 at position R904* of ATL samples (Fig.2a). This
was interesting because early termination of MLL3 is
predicted to produce a dominant negative form with
oncogenic activities [27]. The presence of R904* on a
highly conserved sequence homologous to MLL3
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present on chromosome 13 likely contributed to the
wrong assignment of a snp (rs200662726) in position
R904* of the MLL3 gene in the NCBI database
(Additional file 2: Table S2). Nevertheless, direct sequen-
cing for all ATL DNA samples confirmed LOH for
MLL3 in one ATL patient (Fig.2b and c).
Ten-eleven translocation methylcytosine dioxygenase
genes (TET1-3) are involved in DNA demethylation.
Our investigations reveal mutation in the coding se-
quence of TET1 in 15 % (2/13). The mutation I1229M
has been reported in the cosmic database. We also no-
ticed the presence of TET1 single nucleotide poly-
morphism (snp rs3998860) I1123M. This snp has a
global minor allele frequency (MAF) of 0.3067/1536 but
was detected in all ATL samples tested (Additional file
1: Table S1). A larger cohort study is needed to confirm
these data. No mutations were detected for TET3
(Additional file 1: Table S1). Interestingly, TET2 was
mutated at a high frequency of 38 % (5/13) in ATL pa-
tients. These results are in line with the high rate of
somatic TET2 inactivation observed in MDS, MPN,
chronic myelomonocytic leukemia (CMML) and AML
[28], and they suggest that TET2 may play an important
role in ATL pathogenesis. TET2 LOH was found in two
ATL patients with nonsense mutations at positions
Q876* and Q414* (Fig.3a), two mutations previously re-
ported in CML patients. For these two ATL patients, we
PCR amplified the TET2 region overlapping these muta-
tions and cloned and sequenced five clones for high
tumor grade and matched samples. ATL12 DNA was ex-
tracted from a high grade lymph node biopsy from
megakaryocytes as a tumor negative control. For ATL11
DNA was extracted from high proviral load (high grade
tumor sample) samples before therapy and control sam-
ple DNA obtained after complete remission. Proviral
loads were confirmed by quantitative real time RT-PCR
for all samples (Fig. 1). Both mutations, Q876* and
Q414*, were somatic mutations found in TET2 of ATL
cells and not detected in control samples (Fig.3b and c).
We then analyzed an additional 18 acute ATL patients
by direct PCR, cloning and sequencing and found 6/18
(30 %) with the mutation (Fig. 4). Among missense ATL
mutations only a mutation in position Q414R has
previously been reported, although it was Q414L
Fig. 2 a Schematic representation of the MLL3 protein and distribution of mutations found in ATL patients. Nonsense and missense mutations found
in ATL patients are shown in red and blue, respectively. b Chromatogram of the sequence of MLL3 from normal PBMC DNA (top) and MLL3 from ATL
DNA with amino acid 904 nonsense mutation (bottom). c Alignment of ATL patient DNA KOE with MLL3 demonstrates the presence of a stop codon
TGA in position 904. SNPs identifying the MLL3 sequence (different from Chr13) are labeled in red
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(COSM1618223). Of note, we found another unrelated
ATL patient with a Q876* mutation suggesting this may
represent a frequently mutated region for ATL (Fig. 4).
Discussion
In this study we report a high frequency of TET2 mis-
sense mutations (8/31 (25 %)) and LOH of TET2 (3/31
(10 %)) in acute ATL patients. These data suggest that
TET2 may be involved in HTLV-I pathogenesis and war-
rant additional studies. Studies have shown that the
TET2 mutation results in global low levels of 5hmC
compared with normal controls, supporting a functional
relevance of TET2 mutations in leukemogenesis. Acti-
vating mutations of IDH1/2 have been shown to be mu-
tually exclusive with mutations of TET2 [29]. Although
mutations of IDH1/IDH2 have the same final epigenetic
effect as TET2 inactivation, mainly a global promoter
hypermethylation, mutation in IDH1/2 was not observed
in any ATL samples tested here. Consistent with this no-
tion, increased methylation of CDKN2A promoter has
been associated with the progression of ATL disease
[30]. Wilms tumor (WT1) mutant AML patients have
reduced 5hmC levels similar to the TET2/IDH1/IDH2
mutant in AML, suggesting that WT1 may also play an
important role in control of the epigenome [31]. WT1
and TET2 interact with one another. Although there are
no reports regarding the genetic status of WT1 in ATL
cells, we have previously shown PI3K-dependent cyto-
plasmic retention and inactivation of WT1 in HTLV-I
transformed cells [32]. It will be interesting to evaluate
the role of cytoplasmic WT1 in the regulation of TET2
functions in HTLV-I transformed T cells. Although a
number of genes have been shown to be hypo- or hyper-
methylated in ATL cells, a direct implication of these
genes in cellular transformation and/or ATL pathogen-
esis is lacking. In this study, we also found LOH in 1/13
Fig. 3 a Schematic representation of TET2 protein and distribution of mutations found in ATL patients. (b and c) Somatic LOH Q414* and LOH
Q876* were confirmed by direct sequencing and analyses of TA clones from high grade tumor and matched non-tumor of two ATL samples
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ATL patient for MLL3. ASCOM-MLL3 has a redundant
but crucial role in transactivation of p53 and participates
in DNA damage-induced expression of p53-targeted
genes [33]. Notably, p53 transcriptional functions are
impaired in ATL patients in the absence of genetic mu-
tations in p53 [34] and the possibility that loss of MLL3
participates in this process for some ATL patients war-
rants future studies.
Conclusions
In summary, this report used both next generation se-
quencing and classic direct sequencing methods to iden-
tify mutations of epigenetic regulators in freshly isolated
uncultured ATL samples. This study identifies for the
first time mutations in multiple genes involved in the
maintenance of the epigenome. Notably, a high fre-
quency of mutation was detected in the TET2 gene with
the presence of nonsense mutations leading to LOH in
ATL patients. Our data suggest that TET2 and possibly
MLL3 LOH may be involved in ATL pathogenesis and
larger clinical correlative studies will now be needed to
assess the effect on prognosis, diagnosis, and treatment
of ATL.
Key points
 Somatic mutations in TET2 and MLL3 in HTLV-I-
associated human adult T cell leukemia, ATL.
 Inactivation of MLL3 and TET2 may play an
important role in HTLV-I-induced ATL.
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